CR20230122A - Formulaciones de anticuerpos terapéuticos - Google Patents

Formulaciones de anticuerpos terapéuticos

Info

Publication number
CR20230122A
CR20230122A CR20230122A CR20230122A CR20230122A CR 20230122 A CR20230122 A CR 20230122A CR 20230122 A CR20230122 A CR 20230122A CR 20230122 A CR20230122 A CR 20230122A CR 20230122 A CR20230122 A CR 20230122A
Authority
CR
Costa Rica
Prior art keywords
therapeutic antibody
antibody formulations
pharmaceutical formulations
stable pharmaceutical
formulations
Prior art date
Application number
CR20230122A
Other languages
English (en)
Inventor
Aaron Paul Markham
Justin Cody Thomas
Galen Huaiqiu Shi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20230122A publication Critical patent/CR20230122A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pain & Pain Management (AREA)

Abstract

Formulaciones farmacéuticas estables para anticuerpos terapéuticos anti-IL-23p19 y métodos para usar tales formulaciones farmacéuticas estables.
CR20230122A 2020-09-10 2021-09-10 Formulaciones de anticuerpos terapéuticos CR20230122A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063076600P 2020-09-10 2020-09-10
PCT/US2021/049773 WO2022056202A1 (en) 2020-09-10 2021-09-10 Therapeutic antibody formulations

Publications (1)

Publication Number Publication Date
CR20230122A true CR20230122A (es) 2023-04-14

Family

ID=78232370

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230122A CR20230122A (es) 2020-09-10 2021-09-10 Formulaciones de anticuerpos terapéuticos

Country Status (21)

Country Link
US (1) US20230322913A1 (es)
EP (1) EP4210749A1 (es)
JP (3) JP2023541249A (es)
KR (2) KR20230066592A (es)
CN (1) CN116437963A (es)
AR (1) AR123477A1 (es)
AU (2) AU2021339759B2 (es)
BR (1) BR112023002984A2 (es)
CA (1) CA3191114A1 (es)
CL (2) CL2023000667A1 (es)
CO (1) CO2023002864A2 (es)
CR (1) CR20230122A (es)
DO (1) DOP2023000048A (es)
EC (1) ECSP23017107A (es)
IL (1) IL301104A (es)
JO (1) JOP20230055A1 (es)
MX (1) MX2023002889A (es)
PE (1) PE20231191A1 (es)
TW (2) TWI904235B (es)
UA (1) UA130469C2 (es)
WO (1) WO2022056202A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024349247A1 (en) * 2023-09-27 2026-04-16 Samsung Bioepis Co., Ltd. Stable liquid formulation of anti-il-23 antibody

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004266131C1 (en) 2003-08-12 2010-12-16 Eli Lilly And Company Medication dispensing apparatus with triple screw threads for mechanical advantage
HUE045180T2 (hu) 2004-03-30 2019-12-30 Lilly Co Eli Gyógyszeradagoló készülék az utolsó adag beadása által aktivált rugós zárolófunkcióval
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
EA027032B1 (ru) 2010-03-01 2017-06-30 Эли Лилли Энд Компани Автоматическое инъекционное устройство с замедлителем, включающим смещающий элемент с двойственной функцией
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
CA2866624C (en) 2012-03-07 2022-06-28 Deka Products Limited Partnership Infusion pump assembly
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
AR112341A1 (es) * 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
EP3810268A1 (en) * 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法

Also Published As

Publication number Publication date
WO2022056202A1 (en) 2022-03-17
CL2024004013A1 (es) 2025-03-21
JOP20230055A1 (ar) 2023-03-09
CN116437963A (zh) 2023-07-14
JP2025121902A (ja) 2025-08-20
AU2021339759B2 (en) 2025-11-27
JP7842164B2 (ja) 2026-04-07
DOP2023000048A (es) 2023-04-30
JP2023541249A (ja) 2023-09-29
PE20231191A1 (es) 2023-08-15
KR20250167134A (ko) 2025-11-28
AU2021339759A1 (en) 2023-03-16
CO2023002864A2 (es) 2023-03-27
JP2025000635A (ja) 2025-01-07
CA3191114A1 (en) 2022-03-17
UA130469C2 (uk) 2026-02-25
ECSP23017107A (es) 2023-04-28
EP4210749A1 (en) 2023-07-19
KR20230066592A (ko) 2023-05-16
IL301104A (en) 2023-05-01
MX2023002889A (es) 2023-04-18
AR123477A1 (es) 2022-12-07
US20230322913A1 (en) 2023-10-12
TW202428304A (zh) 2024-07-16
TW202224702A (zh) 2022-07-01
TWI904235B (zh) 2025-11-11
CL2023000667A1 (es) 2023-09-15
BR112023002984A2 (pt) 2023-04-04
AU2026200852A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
PH12021551916A1 (en) Therapeutic antibody formulation.
PH12021550096A1 (en) Compositions of fcrn antibodies and methods of use thereof
EA201991526A1 (ru) Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток
WO2021076554A8 (en) Antibodies targeting flt3 and use thereof
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
MA53765B2 (fr) Tubulysines et conjugués tubulysines-protéines
PH12021551494A1 (en) Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
PH12023550032A1 (en) Tubulysins and protein-tubulysin conjugates
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
MX2025005088A (es) Métodos para tratar cánceres
MX2024013980A (es) Conjugados de glucocorticoides y anticuerpos contra el factor de necrosis tumoral alfa humano
CR20230122A (es) Formulaciones de anticuerpos terapéuticos
IL320329A (en) CD70 antibody drug conjugates and methods of using them
WO2022023566A3 (en) Cd-3 antibodies for the treatment of coronavirus
TW202617183A (zh) 治療性抗體調配物
MX2024004013A (es) Composiciones liquidas orales de enzalutamida.
MX2023015206A (es) Formulaciones de anticuerpos anti-tgf-beta y su uso.
MX2025015337A (es) Anticuerpos de nectina-4 y conjugados anticuerpo-farmaco
MX2024016091A (es) Formulaciones de anticuerpos anti-pd-1
CR20200552A (es) Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
EA202191990A1 (ru) Состав терапевтического антитела
TW202617781A (zh) Ｎｅｃｔｉｎ－４抗體及抗體藥物結合物